Madrigal Pharmaceuticals, Inc.SEC Filings
|
|
All SEC filings by Madrigal Pharmaceuticals, Inc. (MDGL) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Jul 30, 2026 | |
| 10-Q | Quarterly report | View Diff | May 6, 2026 | |
| ARS | Annual report to shareholders | Apr 28, 2026 | ||
| 10-K | Annual report | View Diff | Feb 19, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 4, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 5, 2025 | |
| 10-Q | Quarterly report | View Diff | May 1, 2025 | |
| ARS | Annual report to shareholders | Apr 29, 2025 | ||
| 10-K | Annual report | View Diff | Feb 26, 2025 | |
| 10-Q | Quarterly report | View Diff | Oct 31, 2024 |
Events
| 8-K | Madrigal Appoints John C. Reed, M.d., Ph.d., to Its Board of Directors | Aug 12, 2026 | ||
| 8-K | Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates | Jul 30, 2026 | ||
| 8-K | Current report | Jun 17, 2026 | ||
| 8-K | Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates | May 6, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Apr 28, 2026 | ||
| 8-K | Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results | Feb 19, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | Jan 30, 2026 | ||
| 8-K | Departure of Directors or Certain Officers | Dec 11, 2025 | ||
| 8-K | Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates | Nov 4, 2025 | ||
| 8-K | Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates | Aug 5, 2025 |
Registrations and Prospectuses
| S-8 | Registration of securities for employees | Jun 17, 2026 | ||
| S-8 | Registration of securities for employees | Sep 11, 2025 | ||
| S-8 | Registration of securities for employees | Jun 20, 2025 | ||
| S-8 | Registration of securities for employees | Oct 31, 2024 | ||
| 424B3 | Prospectus supplement | May 7, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | May 7, 2024 | ||
| S-3ASR | Automatic shelf registration | May 7, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Mar 20, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Mar 18, 2024 | ||
| 424B5 | Prospectus supplement for primary offering | Oct 2, 2023 |
Proxies
| DEFA14A | Annual Meeting of Shareholders | Apr 28, 2026 | ||
| DEF 14A | Annual Meeting of Shareholders | View Diff | Apr 28, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Apr 29, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 29, 2025 | |
| DEFA14A | Additional proxy soliciting materials | Apr 29, 2024 | ||
| DEF 14A | Definitive proxy | View Diff | Apr 29, 2024 | |
| DEFA14A | Additional proxy soliciting materials | May 1, 2023 | ||
| DEF 14A | Definitive proxy | View Diff | May 1, 2023 | |
| PRE 14A | Preliminary proxy | Apr 21, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | May 2, 2022 |
Other
| UPLOAD | Letter from SEC | Jan 25, 2024 | ||
| CORRESP | Correspondence with SEC | Jan 17, 2024 | ||
| UPLOAD | Letter from SEC | Jan 3, 2024 | ||
| CORRESP | Correspondence with SEC | Dec 14, 2023 | ||
| CORRESP | Correspondence with SEC | Dec 8, 2023 | ||
| UPLOAD | Letter from SEC | Nov 21, 2023 | ||
| CT ORDER | Confidential treatment order | Mar 12, 2019 | ||
| EFFECT | Notice of effectiveness | Jul 25, 2017 | ||
| CORRESP | Correspondence with SEC | Jul 21, 2017 | ||
| UPLOAD | Letter from SEC | Jul 21, 2017 |
Ownership
| 144 | Notice of proposed sale of securities | Sep 28, 2026 | ||
| 4 | Sibold William John | Sep 11, 2026 | ||
| 144 | Notice of proposed sale of securities | Sep 11, 2026 | ||
| 144 | Notice of proposed sale of securities | Sep 9, 2026 | ||
| 4 | Kelley Shannon T | Aug 20, 2026 | ||
| 144 | Notice of proposed sale of securities | Aug 20, 2026 | ||
| 4 | Reed John C | Aug 18, 2026 | ||
| 3 | Reed John C | Aug 18, 2026 | ||
| SC 13G/A | Blackrock, Inc. Updates Stake in Madrigal Pharmaceuticals, Inc. | Jul 29, 2026 | ||
| 4 | Sibold William John | Jul 20, 2026 |